All In Biotech

Drug Trial Radar · NCT04987229

Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects

Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

236

Planned (sponsor's estimate)

Start

Oct 22, 2021

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Alkermes, Inc.Industry
Sponsor type
Industry
First posted
Aug 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the long-term safety and tolerability of OLZ/SAM in pediatric subjects with schizophrenia or Bipolar I disorder

Conditions

  • Bipolar I Disorder
  • Schizophrenia

Interventions

  • OLZ/SAMDrug

    Olanzapine and Samidorphan fixed dose coated tablet taken once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: Up to 52 weeks

Locations

35 sites in 5 countries. Site status is shown where the registry gives one.

  • Alkermes Investigational Site

    Dothan, Alabama

  • Alkermes Investigational Site

    Little Rock, Arkansas

  • Alkermes Investigational Site

    Stanford, California

  • Alkermes Investigational Site

    Washington D.C., District of Columbia

  • Alkermes Investigational Site

    Miami Lakes, Florida

  • Alkermes Investigational Site

    Decatur, Georgia

  • Alkermes Investigational Site

    Chicago, Illinois

  • Alkermes Investigational Site

    Indianapolis, Indiana

  • Alkermes Investigational Site

    Saint Charles, Missouri

  • Alkermes Investigational Site

    Lincoln, Nebraska

  • Alkermes Investigator Site

    New York, New York

  • Alkermes Investigational Site

    Cincinnati, Ohio

  • Alkermes Investigational Site

    West Chester, Ohio

  • Alkermes Investigational Site

    Richmond, Virginia

  • Alkermes Investigational Site

    Everett, Washington

  • Alkermes Investigational Site

    Córdoba, Argentina

  • Alkermes Investigational Site

    Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina

  • Alkermes Investigational Site

    La Plata, Buenos Aires, Argentina

  • Alkermes Investigational Site

    Buenos Aires, Buenos Aires F.D., Argentina

  • Alkermes Investigational Site

    Mendoza, Mendoza Province, Argentina

  • Alkermes Investigational Site

    Goiânia, Brazil

  • Alkermes Investigational Site

    São Paulo, Brazil

  • Alkermes Investigational Site

    Fortaleza, Ceará, Brazil

  • Alkermes Investigational Site

    Curitiba, Paraná, Brazil

  • Alkermes Investigational Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Alkermes Investigational Site

    São Paulo, São Paulo, Brazil

  • Alkermes Investigational Site

    Barranquilla, Colombia

  • Alkermes Investigational Site

    Bello, Colombia

  • Alkermes Investigational Site

    Bogotá, Colombia

  • Alkermes Investigational Site

    Pereira, Colombia

  • Alkermes Investigational Site

    León, Guanajuato, Mexico

  • Alkermes Investigational Site

    Monterrey, Nuevo León, Mexico

  • Alkermes Investigational Site

    Monterrey, Nuevo León, Mexico

  • Alkermes Investigational Site

    Culiacán, Sinaloa, Mexico

  • Alkermes Investigational Site

    Gustavo A. Madero, State of Mexico, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.